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C A N C E R
The H3K36me2 writer-reader dependency  
in H3K27M-DIPG
Jia-Ray Yu1,2†, Gary LeRoy1,2†, Devin Bready3, Joshua D. Frenster3,  
Ricardo Saldaña-Meyer1,2, Ying Jin4, Nicolas Descostes1,2,5, James M. Stafford1,2,6,  
Dimitris G. Placantonakis3,7,8,9,10, Danny Reinberg1,2*
Histone H3K27M is a driving mutation in diffuse intrinsic pontine glioma (DIPG), a deadly pediatric brain tumor. 
H3K27M reshapes the epigenome through a global inhibition of PRC2 catalytic activity and displacement of 
H3K27me2/3, promoting oncogenesis of DIPG. As a consequence, a histone modification H3K36me2, antagonis-
tic to H3K27me2/3, is aberrantly elevated. Here, we investigate the role of H3K36me2 in H3K27M-DIPG by tackling 
its upstream catalyzing enzymes (writers) and downstream binding factors (readers). We determine that NSD1 
and NSD2 are the key writers for H3K36me2. Loss of NSD1/2 in H3K27M-DIPG impedes cellular proliferation and 
tumorigenesis by disrupting tumor-promoting transcriptional programs. Further, we demonstrate that LEDGF 
and HDGF2 are the main readers mediating the protumorigenic effects downstream of NSD1/2-H3K36me2. Treat-
ment with a chemically modified peptide mimicking endogenous H3K36me2 dislodges LEDGF/HDGF2 from chro-
matin and specifically inhibits the proliferation of H3K27M-DIPG. Our results indicate a functional pathway of 
NSD1/2-H3K36me2-LEDGF/HDGF2 as an acquired dependency in H3K27M-DIPG.
INTRODUCTION
H3K27M is a driver mutation in 80% of diffuse midline glioma 
(DMG), a malignant, treatment-resistant brain tumor that includes 
diffuse intrinsic pontine glioma (DIPG), arising from the pons as 
well as other gliomas in the thalamus and spinal cord (1–3). Patients 
affected by this disease typically range from 5 to 7 years old and 
have a 5-year survival rate of less than 2% with an average postdiag-
nostic survival of 9 months (4, 5). The hallmark of H3K27M DMG/
DIPG is a global loss in chromatin-associated di- and trimethylated 
lysine-27 of histone H3 (H3K27me2/me3) (6, 7). H3K27me1/me2/
me3 is catalyzed solely by the polycomb repressive complex 2 (PRC2) 
(8, 9). Notably, PRC2 is allosterically stimulated by its own catalytic 
product, H3K27me3, fostering a positive feedback loop (10, 11). This 
mechanism by which PRC2 “writes” and “reads” H3K27me3 is central 
to the spreading and formation of extensive H3K27me3-chromatin 
domains, which provide the platform for chromatin compaction and 
thus repression (12). These H3K27me3-chromatin domains are also 
inherited upon DNA replication (13). The inheritance of H3K27me3 
together with the PRC2 “write-read” mechanism can fully restore 
H3K27me3-chromatin domains upon DNA replication (13). This 
unique property of PRC2 points to its critical role in propagating a 
particular cellular identity. However, as reported by our laboratory 
and others, H3K27M inhibits PRC2 catalysis of H3K27me2/me3 in 
multiple ways (6, 14). H3K27M preferentially binds to the allosteri-
cally activated state of PRC2, thereby hindering this crucial feedback 
mechanism leading to a global loss of H3K27me3 (14). This phenomenon 
not only disrupts the formation of extensive H3K27me3-repressive 
domains but also is expected to impact their inheritance. Expectedly, 
H3K27M-mediated dysregulation of this critical epigenetic state 
fosters genomic derepression and aberrant activation of inappro-
priate genes that potentially cooperate with other genetic mutations 
in driving early oncogenesis during tumor evolution.
Previously, we and others reported that H3K27M DIPG cells ex-
hibit elevated levels of another chromatin-associated histone post-
translational modification, demethylated lysine-36 of histone H3 
(H3K36me2) (14–16). While H3K36me2 is antagonistic to the ca-
talysis of H3K27me2/me3 (17, 18), it remains unclear as to whether 
the elevated levels of H3K36me2  in DIPG arise through the in-
creased levels of transcription in these cells or letup from the antag-
onistic effects of H3K27me2/me3. The role of these elevated levels 
of H3K36me2  in promoting tumorigenesis is also unclear. Five 
mammalian lysine methyltransferases can “write,” i.e., catalyze, his-
tone H3K36 methylation, generating H3K36me1 and H3K36me2: 
NSD1, NSD2, NSD3, ASH1L, and SETD2 (19–21). Among these 
enzymes, only SETD2 can further convert H3K36me2 to H3K36me3 
(21), the latter being closely associated with transcribed gene bodies 
and with the recruitment of RNA splicing factors through direct 
protein-protein interactions (22). However, unlike H3K36me3, the 
distribution of H3K36me2 is less restricted and appears to be gener-
ally associated with euchromatic regions (23). Both H3K36me2 and 
H3K36me3 are recognized by downstream proteins, “readers,” that 
contain one or more methyl-lysine reading Pro-Trp-Trp-Pro (PWWP) 
domains (24). Among these readers, we previously demonstrated 
that LEDGF and HDGF2 are associated with all H3K36me2/me3- 
decorated genomic regions and facilitate RNA polymerase II–
dependent transcription by relieving the nucleosomal barrier, 
functionally resembling the FACT complex (25). Other PWWP- 
containing readers, such as DNMT3A and DNMT3B, have been shown 
to localize to intergenic regions and to regulate DNA methylation 
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patterns (26). Here, we investigate the role of H3K36me2 by tackling 
its writers and readers to ascertain the contribution of any of these 
writer-reader modules in establishing dependency on H3K36me2 in 
H3K27M DIPG cells.
RESULTS
NSD1 and NSD2 are responsible for global H3K36me2 levels 
and required for H3K27M-DIPG proliferation
To probe the functional role of the aberrant elevation of H3K36me2 
in H3K27M-DIPG cells, we first engineered a doxycycline-inducible 
H3K36M construct in DIPG4 cells comprising a H3K27M muta-
tion. H3K36M is a general inhibitor of H3K36 methyltransferases, 
and its expression in DIPG4 cells effectively reduced endoge-
nous H3K36me2/3 levels and impeded cell proliferation by an MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay 
(Fig. 1A). To ascertain the writers that are responsible for H3K36me2 
catalysis in the context of DIPG, we adopted a small interference 
RNA (siRNA)–based approach by knocking down NSD1 alone and 
in conjunction with each of the remaining H3K36 methyltransfer-
ases in DIPG4 cells. Knockdown (KD) of NSD1 alone in DIPG4 had 
a moderate effect on endogenous H3K36me2 levels, and co-KD of 
NSD2 manifested an additional effect, whereas co-KD of NSD3, 
ASH1L, or SETD2 was ineffectual (Fig. 1B, left). Consistent with the 
literature, SETD2 is the only mammalian enzyme responsible for 
H3K36me3. While co-KD of NSD1 and NSD2 had a substantial im-
pact on H3K36me2 levels, additional KD of NSD3, ASH1L, or SETD2 
was ineffectual (Fig. 1B, right). We further extended our analysis to 
other DIPG cell lines, including DIPG6 (H3K27M), DIPG13 (H3K27M), 
DIPG38 (H3K27M), DIPG10 [H3–wild type (WT)], and a cortex 
glioma cell line, pcGBM2 (H3-WT) (Fig. 1C and figs. S1, A and B). 
While single KD of NSD1 in pcGBM2 and KD of NSD2 in DIPG13 
rendered a major effect on H3K36me2 levels, their co-KD demonstrated 
a more substantial effect on eliminating endogenous H3K36me2 
levels (Fig. 1C and fig. S1B). Intriguingly, co-KD of NSD1 and NSD2 
appeared to strongly reduce the proliferation of three H3K27M 
DIPG cell lines analyzed (DIPG6, DIPG13, and DIPG38) (Fig. 1D 
and fig. S1C), but a considerably milder effect was observed in 
H3-WT cells, including DIPG10 or human embryonic kidney 293T 
(HEK293T) cells (Fig. 1D and fig. S1D).
LEDGF and HDGF2, but not DNMT3A and DNMT3B, are 
essential for proliferation of H3K27M-DIPG
Having established that NSD1/2 is crucial for the chromatin depo-
sition of H3K36me2 and the proliferation of H3K27M-DIPG cells, 
we next investigated which readers might mediate the downstream 
effects. Among the PWWP domain–containing proteins, LEDGF, 
HDGF2, DNMT3A, and DNMT3B appeared to have preferential 
binding to H3K36me2/me3 peptides and nucleosomes (24). KD of 
LEDGF and/or HDGF2 had little impact on H3K36me2 levels in 
DIPG4 cells (Fig. 1E). Similar to the single KDs of NSD1 and NSD2, 
a moderate reduction in proliferation was observed in the single KD 
of HDGF2 in DIPG4 cells and the single KD of LEDGF or HDGF2 in 
DIPG13 cells, while their co-KD exhibited a far more substantial 
impact on DIPG4 and DIPG13 cells (Fig.  1F). Further, co-KD of 
LEDGF and HDGF2 had only a very mild effect on the proliferation 
of DIPG10 (H3-WT) cells (fig. S1E). On the other hand, neither the 
single nor the joint KDs of DNMT3A and DNMT3B had a notable 
impact on cell proliferation (fig. S1F). At the cellular levels, co-KD 
of NSD1 and NSD2 as well as co-KD of LEDGF and HDGF2 
induced a G1/S cell cycle arrest and a reduced expression of prolif-
eration marker gene, Ki67, but had no impact on apoptotic markers, 
cleaved poly(ADP-ribose) polymerase and caspase 3, in H3K27M-
DIPG cells (fig. S1, G and H).
NSD1/2 and LEDGF/HDGF2 facilitate H3K27M-DIPG tumor 
growth in vivo
Next, we implanted these stable KD cell lines using lentivirus-based 
short hairpin RNAs (shRNAs) in a xenograft mouse model via an 
intracranial injection in the cerebral hemisphere. Of note, DIPG4 does 
not steadily form tumors in the brain in NOD/SCID/IL2 (NSG) mice 
although it has been reported to form tumors by flank injections 
in nude mice (27). As DIPG13 is more dependent on NSD2 for its 
H3K36me2 levels, KD of NSD2 exhibited reduced tumor size and 
extended survival of recipient mice relative to control and the NSD1 
KD group, and this effect was further amplified in the NSD1 and NSD2 
co-KD group (Fig. 2A). Similarly, KD of LEDGF or HDGF2 alone 
exhibited a partial effect on reducing tumor size and extending mice 
survival, while their co-KD manifested a much more robust effect (Fig. 2B). 
Of note, we have observed a rapid selection advantage of clones that 
escaped from shRNA-mediated KD in cultured H3K27M-DIPG cells, 
likely due to the strong inhibition of cell proliferation by shRNAs. 
We further confirmed that the engrafted tumors formed in NSG mice 
also escaped from shRNA KD by examining the end-stage tumor 
lysates from control and double KD (dKD) groups (fig. S2, A and B).
LEDGF/HDGF2 spread with H3K36me2, correlating 
with mRNA expression
As loss-of-function of LEDGF/HDGF2 phenocopied that of NSD1/2, 
we speculated that LEDGF/HDGF2 function as the main readers 
that mediate the downstream effect of NSD1/2 in regulating gene 
expression profiles and pathways in the context of DIPG. Chroma-
tin immunoprecipitation sequencing (ChIP-seq) of H3K36me2, 
LEDGF, and HDGF2 gave evidence of a general positive correlation 
among their chromatin occupancies (Fig. 3A) (25). In a comparison 
between H3-WT and H3K27M DIPG cells, the enriched occupancy of 
LEDGF/HDGF2 correlated highly with the spreading of H3K36me2 
at derepressed loci elicited by H3K27M, in stark contrast to those 
genes decorated by H3K27me3 shown by heatmaps and metapro-
files of ChIP-seq (Fig. 3A and fig. S3, A and B). Genes with higher 
messenger RNA (mRNA) expression levels by RNA sequencing 
(RNA-seq) exhibited substantially higher enrichments in H3K36me2, 
LEDGF, and HDGF2 occupancies by ChIP-seq (Fig. 3B). Further-
more, in an isogenic HEK293T-based system with inducible H3 his-
tone, either WT or H3K27M, we consistently observed increased 
LEDGF/HDGF2 occupancy at genes that had lost H3K27me3 and 
gained H3K36me2 upon induction of the H3K27M oncohistone 
(Fig. 3C). Next, we generated NSD1 and NSD2 knockout (KO) lines 
in DIPG13 cells by using CRISPR-Cas9 to disrupt the respective 
catalytic SET domain. Consistent with RNA interference–based re-
sults, NSD2-KO cells exhibited extremely poor proliferation and 
very low H3K36me2 levels, whereas changes in these criteria were 
almost inconsequential in the NSD1-KO cells (fig. S4A). NSD2-KO 
cells also exhibited largely reduced chromatin occupancies of 
LEDGF and HDGF2 (Fig. 3D). Together, these data ascertain the 
hierarchical relationship of NSD1/2-LEDGF/HDGF2 in regulating 
gene expression in DIPG cells. Of note, we were unable to obtain a 
NSD1/2 double KO (dKO) line in DIPG13, and the NSD2-KO lines 
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were barely maintainable, becoming very sensitive to lentiviral in-
fection and the selection process, thereby preventing a successful 
rescue using a WT NSD2 complementary DNA. In parallel, we also 
generated an NSD1 and NSD2 dKO by CRISPR-Cas9 in HEK293T 
cells and corroborated that loss of NSD1/2 and H3K36me2 only 
slightly affected its proliferation (figs. S1D and S4B).
NSD1/2 and LEDGF/HDGF2 control protumorigenic gene 
expression signatures
We then investigated the functional consequence to gene expres-
sion profiles and the pathways affected upon loss of NSD1/2 or 
LEDGF/HDGF2 in DIPG13 cells. We performed RNA-seq analysis 
using NSD2-KO cells in which we transiently knocked down NSD1 
using siRNAs (NSD2-KO  +  siNSD1), as well as LEDGF/HDGF2 
dKD cells. By gene set enrichment analysis (GSEA), we detected 
the down-regulation of a total of 1208 previously established gene 
signatures/pathways in NSD2-KO + siNSD1 cells (clone #7), two-thirds 
(788 of 1208, 65%) of which overlapped with those down-regulated 
in LEDGF/HDGF2 dKD cells (Fig. 4A, left). A similar result (752 of 
1129, 66%) was observed in a second independent NSD2-KO clone 
(clone #10) (Fig. 4A, right). The high-ranked overlapping signatures/
pathways included ESC stemness gene signature, CHEK2 pathway, 
epidermal growth factor receptor (EGFR) signaling, MYC targets, 
pre-B lymphocyte developmental genes, and hypoxia–down-regulated 
genes (Fig. 4B and fig. S5A), indicating that the NSD1/2-H3K36me2-
LEDGF/HDGF2 writer-reader module is necessary for maintaining 
the distinctive tumorigenic gene expression pattern in H3K27M 
DIPG cells (Fig. 4B). Of note, the down-regulated pathways in 
NSD2-KO cells are highly overlapped with those in NSD2-KO + 
siNSD1 cells since DIPG13 cells are mainly dependent on NSD2 for 
its endogenous H3K36me2 levels (fig. S5B). On the other hand, co-KD 
of DNMT3A and DNMT3B exhibited some, but less, correlation 
with loss of NSD1/2 as gauged by RNA-seq and GSEA analyses (fig. 
S5C). Moreover, 42.7% (516 of 1208) of down-regulated pathways 
Fig. 1. NSD1/2 and LEDGF/HDGF2 are required for H3K27M-DIPG cell proliferation. (A) Left: Western blot of H3K36me2, H3K36me2, histone H3, and Flag in DIPG4 
(H3K27M) cells expressing doxycycline-inducible, flag-tagged H3-WT or H3K36M constructs. Doxycycline (Dox; 0, 1, or 5 ng/ml) was administrated for an induction of 
ectopic histones. Cell lysates were harvested 3 days after induction. Right: An MTT assay was conducted for assessing the proliferation of cells treated with respective 
conditions in the left panel. Cells were seeded 3 days after induction and the MTT assay was conducted 6 days after induction. (B) Western blot of glyceraldehyde- 3-
phosphate dehydrogenase (GAPDH), H3K36me2, H3K36me3, and histone H3 in DIPG4 cells transfected with indicated siRNAs, including NSD1 and NSD2, NSD3, ASH1L, 
or SETD2. (C) Western blot of NSD1, NSD2, GAPDH, H3K36me2, and histone H3 in DIPG10 (H3-WT), DIPG6 (H3K27M), and DIPG13 (H3K27M) cells transfected with and 
without siRNAs against NSD1 and/or NSD2. Asterisks indicate nonspecific bands detected by an anti-NSD1 antibody (Bethyl Laboratories, no. A300-BL715). Cell lysates 
were harvested 3 days after transfection, and GAPDH was used as a loading control in (B) and (C). (D) Proliferation assays of DIPG10, DIPG6, and DIPG13 cells stably ex-
pressing control or shRNAs against NSD1 and/or NSD2. Cell numbers were counted after 2, 4, and 6 days. (E) Western blot of LEDGF, HDGF2, GAPDH, H3K36me2, and 
histone H3 in DIPG4 cells stably expressing control or shRNAs against LEDGF and/or HDGF2. (F) Proliferation assays of DIPG4 cells used in (E) and DIPG13 cells with the 
same conditions. rTTA, reverse tetracycline-controlled transactivator; EV, empty vector. *P < 0.05, **P < 0.01, and ***P < 0.001 by Student’s t test.
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in NSD2-KO + siNSD1 and 41.4% (754 of 1822) of those in LEDGF/
HDGF2-dKD cells are overlapped with those in H3K27M (DIPG13) 
when being compared to H3-WT (DIPG10) cells (fig. S5D), corrob-
orating a relevance of H3K36me2-dysregulated pathways being 
adapted in H3K27M cells.
H3K36me2-mimicking peptide inhibits H3K27M-DIPG 
proliferation by displacing chromatin-bound LEDGF/HDGF2
Last, we adopted a chemical approach to tackle the H3K36me2 
writer-reader pathway. We engineered a transportable H3K36me2 
peptide comprising a cell-penetrating peptide (CPP) of 11 amino 
acids derived from an HIV TAT protein–based cell membrane en-
try signal, in a disulfate bond fusion with an H3 peptide (amino 
acids 21 to 43) having a dimethyl chemical modification at lysine-36 
(H3K36me2-CPP) (Fig. 4C). The CPPs enter the nucleus as evi-
denced by the literature (28). Upon cell entry, the disulfate bond is 
reduced in the intracellular redox environment, and the released 
H3K36me2 peptide acts as an endogenous competitive inhibitor 
against the PWWP domains of LEDGF and HDGF. Notably, incuba-
tion with this peptide largely reduced the proliferation of H3K27M 
DIPG cells (DIPG6 and DIPG13) but had little impact on that of 
H3-WT cells (DIPG10 and pcGBM2) (Fig. 4D). A treatment includ-
ing extended titrations of H3K36me2-CPP further demonstrated 
that the median inhibitory concentration of H3K36me2-CPP for 
DIPG13 is ~173 M (fig. S5E). Treatment with H3K36me2-CPP in 
DIPG13 cells competitively dislodged endogenous LEDGF and 
HDGF2 from chromatin, pointing to its functional efficacy, and 
such effects appear to be general and genome-wide as evident by 
examining genes with high or low enrichment of H3K36m2 or 
H3K36me3, respectively (Fig. 4E). Of note, H3K36me2-CPP was 
more efficient at dislodging LEDGF relative to HDGF2, possibly 
due to HDGF2 having a stronger preferential binding to H3K36me3 
peptides and nucleosomes than LEDGF (24, 25).
DISCUSSION
Similar to the case of PRC2 and H3K27me3, NSD1/2 and H3K36me2 
are essential for normal development but also play pleiotropic and 
context-dependent roles in human cancer (29). For example, inacti-
vating mutations in NSD1 were frequently found in head and neck 
cancers (30), whereas an activating NUP98-NSD1 fusion protein 
that arises from a chromosomal translocation drives leukemogene-
sis in human acute myeloid leukemia (31, 32), and further, a gain-
of-function mutation in NSD2 is present in acute lymphoblastic 
leukemia (33, 34). Here, we established that LEDGF/HDGF2 are 
functional readers mediating protumorigenic effects downstream 
of NSD1/2 in the context of H3K27M-DIPG. H3K27M-DIPG acquire 
a previously unidentified dependency on this H3K36me2 writer- 
reader axis through its maintenance of a tumor-promoting gene 
expression profile. However, the tumor evolution process that leads 
to this acquired dependency following the initial H3K27M-mediat-
ed epigenome remodeling remains to be defined. While NSD1 and 
NSD2 functionally converge, H3K27M-DIPG cell lines exhibited a 
spectrum of dependency on either of them, similar to the case with 
LEDGF and HDGF2. Additional layers of regulation may foster 
such individual differences, including the ratio of expression levels 
and involvement of potential cofactors. In addition, as H3K36me2 
is antagonistic to H3K27me2/me3, depletion of NSD1/2 could par-
tially restore H3K27me3 at some normally repressed loci, which 
might also contribute to a tumor-inhibiting effect even with the 
presence of H3K27M in DIPG cells, as implied by a recent study 
reporting the generation of an isogenic DIPG system (16).
Importantly, these H3K36me2 writers and readers can be poten-
tially targeted by pharmacological approaches through their func-
tional domains, such as the PWWP domains and the SET domains 
of NSD1/2. However, extensive efforts to target the SET domains of 
NSD proteins with potent inhibitors have proven unsuccessful at 
the nanomolar scale. In this regard, a recent cryo–electron micros-
copy study revealed that a series of residues within and flanking the 
Fig. 2. KD of NSD1/2 or LEDGF/HDGF2 delays tumor onset and extends survival 
in a xenograft mouse model. (A) Left: A Kaplan-Meier survival curve plot of mice 
bearing xenograft tumors with endpoints defined by a sign of distress. DIPG13 cells 
stably expressing a firefly luciferase and control or shRNAs against NSD1 and/or 
NSD2 were implanted in the cortex of NSG mice by intracranial injection. A total of 
250,000 cells were implanted in each mouse (n = 10 mice for each condition). Right: 
A quantification of firefly luciferase signals in mice described in the left panel. Bio-
luminescent imaging (BLI) data were presented at day 35 after injection before the 
first mouse exhibited a sign of distress. Bottom: Representative BLI images from 
indicated conditions. (B) Left: A Kaplan-Meier survival curve of mice implanted with 
DIPG13 cells stably expressing control or shRNAs against LEDGF and/or HDGF2 in 
the same experimental conditions described in (A) (n = 10 mice for control; n = 5 
for shLEDGF; n = 4 for shHDGF2; and n = 9 for shLEDGF + shHDGF2). Right: A 
quantification of BLI signals in mice describe in the left panel. Bottom: Representative 
BLI images from indicated conditions. *P < 0.05 and ***P < 0.001 by log-rank test; 
n.s., not significant (P > 0.05) for Kaplan-Meier survival analysis. *P < 0.05, **P < 0.01 
and ***P < 0.001 by a nonparametric Mann-Whitney test for BLI quantifications.
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SET domain are crucial for unwrapping the linker and nucleosomal 
DNA such that an autoinhibitory state inherent to NSD proteins is 
converted to an active conformation (35, 36). Understanding these 
unique features of NSDs could further facilitate the structurally as-
sisted design of new inhibitors. Other pharmacological targeting 
strategies that might function in a more specific manner involve the 
PWWP domains of LEDGF/HDGF2. Fortunately, two selective 
PWWP domain binding ligands have been reported recently by the 
Structural Genome Consortium (www.thesgc.org). Such prototype 
compounds will provide insights into future pharmacological de-
velopment. In addition to H3K27M-DIPG, an impaired PRC2 
activity and loss of H3K27me2/me3 also drive tumorigenesis of sev-
eral other types of cancer, including malignant peripheral nerve 
sheath tumors having frequent genetic deletions in multiple PRC2 
core subunits (37) and posterior fossa type A ependymoma having 
aberrant expression of EZHIP, an endogenous protein that inhibits 
Fig. 3. LEDGF/HDGF2 occupancy on chromatin is dependent on NSD1/2-H3K36me2 and positively correlates with gene expression. (A) Left: Representative ChIP-seq 
tracks of H3K36me2, LEDGF, and HDGF2 chromatin co-occupancy in H3-WT (DIPG10 and pcGBM2) and H3K27M (DIPG4, DIPG6, and DIPG13) cells. Right: Representative 
heatmaps of ChIP-seq for DIPG4 cells centered to H3K36me2- or H3K27me3-enriched genes. (B) Violin plots showing enrichment of H3K36me2, LEDGF, or HDGF2, respec-
tively, for genes categorized as low, mid, or high based on their mRNA expression. The central thick dash line indicates the mean value of each plot; the upper thin dash 
line indicates the top 25% percentile and the lower one for the bottom 25% percentile. (C) Metaprofile plots of H3K27me3, H3K36me2, LEDGF, and HDGF2 ChIP-seq data 
in HEK293T cells ectopically expressing H3-WT or H3K27M for 24 hours. Data were presented within a 500-kb window upstream or downstream from TSS. (D) Top: Meta-
profile plots of LEDGF and HDGF2 occupancy in WT or NSD2-KO DIPG13 cells (clone #7 and clone #10). Bottom: Representative ChIP-seq tracks for the top panel. Overlaid 
panels were presented at the bottom to better illustrate the differences. TSS, transcription start site; TES, transcription end site. ****P < 0.0001 by Student’s t test.
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PRC2 (38–40). The results here expand our understanding of epi-
genetic dysregulations in H3K27M-DIPG and suggest that disrup-
tion of the H3K36me2 pathway should be taken into consideration 
for developing and designing therapeutic interventions for a broad 
spectrum of tumors that exhibit impaired PRC2 activity. Recently, 
several studies have also explored the transcriptional and epigenetic 
vulnerabilities of H3K27M-DIPG and suggested a number of po-
tential targets, including CDK7 of TFIIH, bromodomain proteins 
binding to acetylated histones, and the residual activity of PRC2 
(27, 41, 42). Together with our results, these approaches may pro-
vide a foundation for combinatory therapies.
METHODS
Cell culture
SU-DIPG-4, SU-DIPG-6, SU-DIPG-13, and SU-DIPG-38 cells are 
gifts from the laboratory of M. Monje (Stanford). DIPG-N is gener-
ated by D.G.P. at the New York University (NYU). All DIPG cell 
lines were cultured and maintained in tumor stem medium, which 
contains 1:1 mixture of Neurobasal-A and Dulbecco’s Modified Eagle 
Medium (DMEM)/F12 medium (Life Technologies), supplement-
ed with 1% antibiotic/antimycotic solution (Life Technologies), 
2 mM GlutaMAX (Life Technologies), 10 mM Hepes buffer (Life 
Technologies), 1 mM sodium pyruvate (Sigma-Aldrich), 1% MEM 
Fig. 4. NSD1/2 and LEDGF/HDGF2 coregulate protumorigenic pathways and can be disrupted by a H3K36me2-mimicking peptide. (A) Venn diagrams showing 
overlaps of gene signatures/pathways down-regulated in LEDGF/HDGF2 dKD DIPG13 cells and NSD2-KO#7 + siNSD1 or NSD2-KO#10 + siNSD1 DIPG13 cells (P = 4.2 × 10−9 
and 1.8 × 10−4, respectively). The alteration of gene signatures/pathways was detected by GSEA. P values were obtained by the hypergeometric distribution to compute 
the significance of the overlap of two pathway sets. (B) Representative images of highly ranked GSEA signatures/pathways detected in (A), including a CHEK2 pathway, 
an embryonic stem cell (ESC) steamness signature, and a set of EGFR signaling target genes. (C) Top: A schematic illustration of the design of CPP. A HIV-based cell entry 
peptide was linked to a H3K36me2 peptide (histone H3 21 to 43 amino acids, cargo peptide) by a disulfide bond. Bottom: Amino acid sequence of H3K36me2-linked CPP. 
(D) A CellTiter-Glo cell survival assay for H3-WT (DIPG10 and pcGBM2) and H3K27M (DIPG-N and DIPG13) cells treated with control (vehicle only) or H3K36me2-CPP. Cells 
were assayed at 72 hours after dosing with a titration of control or H3K36me2-CPP and data were presented by ratios of CellTiter-Glo signals in control versus H3K36me2-
CPP treated cells. PBS, phosphate-buffered saline. (E) Metaprofiles of ChIP-seq analysis for changes in LEDGF and HDGF2 occupancy of genes enriched with H3K36me2 or 
H3K36me3 and the rest of genes in DIPG13 cells treated with a control vehicle (red) or a H3K36me2-CPP (blue).
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nonessential amino acid solution (Sigma-Aldrich), B-27 supplement 
minus vitamin A (Gibco), human EGF (20 ng/ml) (Shenandoah Bio-
tech), and human fibroblast growth factor (20 ng/ml) (Shenandoah 
Biotech). HEK293T and HEK293-FT cells were maintained in 
DMEM supplemented with 10% fetal bovine serum,1 mM sodium 
pyruvate (Sigma-Aldrich), 2 mM l-glutamine (Sigma-Aldrich), and 
1% penicillin/streptomycin solution (Sigma-Aldrich).
Antibodies
The antibodies used in this study are as follows: LEDGF (Proteintech) 
rabbit polyclonal, catalog no. 25504-1-AP; HDGF2 (Proteintech) 
rabbit polyclonal, catalog no. 15134-1-AP; H3K27me3 (Cell Signaling 
Technology) rabbit monoclonal C36B11, catalog no. 9733; H3K36me2 
(Cell Signaling Technology) rabbit monoclonal C75H12, catalog 
no. 2901; H3K36me3 (Cell Signaling Technology) rabbit monoclo-
nal D5A7, catalog no. 4909; NSD1 (Bethyl Laboratories) rabbit 
monoclonal, catalog no. A300-BL715 (discontinued); NSD1 (Uni-
versity of California, Davis/National Institutes of Health NeuroMab 
Facility) mouse monoclonal, N312/10; NSD2 (Millipore) mouse 
monoclonal 29D1, catalog no. MABE191; NSD3 (Cell Signaling 
Technology) rabbit monoclonal D4N9N, catalog no. 92056; ASH1L 
(Bethyl Laboratories) rabbit polyclonal, catalog no. A301-748A; SETD2 
(Bio-Rad) mouse monoclonal OTI1E1, catalog no. VMA00449; 
glyceraldehyde-3-phosphate dehydrogenase (Cell Signaling Tech-
nology) rabbit monoclonal D16H11, catalog no. 5174; histone H3 
(Abcam) rabbit monoclonal EPR16987, catalog no. ab176842; anti- 
Flag (Sigma-Aldrich) mouse monoclonal M2, catalog no. F1804; 
and H2Av (Active Motif) rabbit polyclonal, catalog no. 39715.
shRNA constructs and lentivirus production
pLKO.1-based shRNAs against NSD1, NSD2, LEDGF, and HDGF2 
were purchased from Sigma-Aldrich for lentiviral production and 
delivery. A lentiviral vector expressing firefly luciferase and mCherry 
was used for bioluminescence imaging experiments (43). For the 
production of viral particles, 10 g of lentiviral vectors were cotrans-
fected with 2.5 g of pcREV, 3 g of BH-10, and 5 g of pVSV-G 
packaging vectors into 293-FT cells. The virus-containing medium 
was collected 48 hours after transfection, and the target cells were 
spin infected. Polybrene was added to the viral medium at a concen-
tration of 8 g/ml. Infected cells were selected by puromycin (1 ng/ml) 
for 2 days, G-418 (400 g/ml) for 5 days, or fluorescence-activated 
cell sorting (FACS)–sorted for mCherry. The target sequence of each 
shRNA used is as follows: NSD1, AGGAGTGGATGGGACATATAA 
(TRCN0000238370); NSD2, CGGAAAGCCAAGTTCACCTTT 
(TRCN0000274182); LEDGF, GCAGCTACAGAAGTCAAGATT 
(TRCN0000286344); and HDGF2, GCAGGAGAGCAGAGCA-
GAGAA (TRCN0000107975).
siRNA transfection
The siRNAs used in this study were purchased from Dharmacon 
(ON-TARGETplus SMARTpool), including the ones against 
NSD1, NSD2, NSD3, ASH1L, SETD2, DNMT3A, and DNMT3B. 
Five nanomoles of each pooled siRNA was transfected into DIPG cells 
at ~50% confluency in six-well plates using Lipofectamine RNAiMAX 
according to the manufacturer’s instructions.
CRISPR-Cas9 genome editing
Single-guide RNAs (sgRNAs) were designed using CRISPR design 
tool in https://benchling.com. All sgRNAs used were cloned in 
pSpCas9(BB)-2A–green fluorescent protein (GFP) (plasmid 48138, 
Addgene). The sgRNAs were transfected into DIPG cells using 
Lipofectamine 2000 (Life Technologies). Single clones from GFP- 
positive cells were isolated individually into each well of 96-well plates 
by FACS. The sequence of sgRNA that targets the SET domain 
of NSD1 is GTAGCTTTACAGTTGCAACG and that of NSD2 is 
CCCACAGATGAGAATCCTTG.
Mouse intracranial injections and bioluminescence imaging
Mice were housed within NYU Langone Medical Center’s Animal 
Facilities. All procedures were performed according to our IACUC 
(Institutional Animal Care and Use Committee)-approved protocol 
as previously described (44). Briefly, 6- to 8-week old NSG-null mice 
were anesthetized by intraperitoneal injection of ketamine/xylazine 
(10 and 100 mg/kg, respectively), mounted on a stereotactic frame 
(Harvard Apparatus), in which a high-speed drill was used to drill a 
hole in the calvaria (2 mm off the midline and 2 mm anterior to the 
coronal suture), and stereotactically injected with 5 l of a suspen-
sion of human DIPG cells (50,000 cells/l) at a depth of 3 mm. Animals 
were imaged for luciferase expression at the time points indicated. 
Mice were injected with luciferin (Gold Biotechnology 115144-35-9) 
at a dose of 200 mg/kg 15 min before imaging on the PerkinElmer 
IVIS Spectrum instrument. The resulting images were analyzed using 
PerkinElmer’s Living Image software package.
ChIP-seq and RNA-seq
ChIP-seq experiments were performed as previously described (11). 
Briefly, cells were cross-linked with 1% formaldehyde for 10 min. 
Following nuclei isolation, the chromatin was extracted and frag-
mented to ~250 base pairs (bp) using a Diagenode Bioruptor. ChIP 
was performed with the specific antibodies listed above. For quanti-
fication, (spike-in) chromatin from Drosophila (1:100 ratio to the 
experimental chromatin) with Drosophila-specific H2Av antibody 
was added to each sample as a spike-in control, allowing ChIPs to 
be compared to one another. Libraries were prepared using 1 to 
30 ng of immunoprecipitated DNA as previously described (45). 
For RNA-seq experiments, RNA was isolated using RNeasy mini 
spin columns (Qiagen) according to the manufacturer’s instruction. 
Total RNA (1 to 5 g) was then processed by oligo(dT) selection 
and library preparation using the Automated KAPA Library 
Prep Kit.
Bioinformatics
ChIP-seq and RNA-seq analyses were processed as previously de-
scribed (11, 14, 25). Briefly, the ChIP-seq data were first mapped to 
human genome (hg38) using the Bowtie2 software package (version 
2.3.0). All reads that failed to align to the human genome were 
mapped to the fly genome (dm6). The total library size was then 
adjusted to the reference genome (fly). MACS2 software package 
(version 2.1.1) was used for calling significantly enriched peaks at a 
false discovery rate less than 5% relative to the input samples. For 
RNA-seq data, STAR (version 2.6.1) (46) and RSEM (version 1.3.2) 
(47) indices were created on the basis of the mouse 10 ensemble 
genome and gene annotations downloaded from UCSC genome 
browser. Paired-end 79-bp reads were directly mapped to this STAR 
index with command line options “--outFilterMismatchNmax 3 
outFilterMultimapNmax 20 --winAnchorMultimapNmax 50 --quantMode 
TranscriptomeSAM GeneCounts.” RSEM software package was then 
used to estimate relative gene expressions with parameter settings 
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“--paired-end --strandedness reverse” on the alignments generated 
by STAR. For all genes with at least one of the libraries above zero 
transcript per million, the average expression values across biologi-
cal replicates were compared between samples for detecting differ-
entially expressed genes, using DESeq2 (48). Gene Ontology (GO) 
term enrichment analysis was performed using DAVID Functional 
Annotation Tool (49). The complete list of GO term categories with 
statistically significant enrichment was extracted. GSEA was con-
ducted using GSEAPreranked (50) software package on differential 
analysis results generated by DESeq2.
Metagene profile analyses
Metagene profiles for Figs. 3C and 4E and fig. S3 were generated 
with deepTools v2.3.3. Genes were divided in three equal categories 
(low, mid, and high) by their RNA-seq counts. Only genes contain-
ing peaks for H3K36me2, LEDGF, and HDGF2, respectively, were 
selected and then plotted (Fig. 3B). Genes with peaks in the control 
condition for H3K36me2 and H3K36me3 were selected and plotted 
for HDGF2 and LEDGF enrichment, respectively, for control and 
H3K36me2-CPP conditions (Fig. 4E). Genes with peaks for K27me3, 
H3K36me2, and H3K36me3, respectively, were selected and then 
plotted for K27me3, H3K36me2, H3K36me3, HDGF2, and LEDGF 
and compared to multiple WT and K27M DIPG cell lines (fig. S3).
CPP treatment
CPPs were purchased from LifeTein. The CPP was reconstituted and 
diluted in phosphate-buffered saline as vehicle. For CellTiter-Glo 
cell survival assays, cells were treated for 72 hours with a titration of 
cell penetrating peptide as indicated. For ChIP-seq, cells were treat-
ed with 250 M CPP or vehicle only (control) for 16 hours and then 
cross-linked with 1% formaldehyde for 10  min and processed 
for ChIP-seq.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/29/eabg7444/DC1
View/request a protocol for this paper from Bio-protocol.
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